Glenmark Pharmaceuticals’ New Jersey-based subsidiary -- Glenmark Pharmaceuticals Inc is recalling over 72,000 units of blood pressure (BP) lowering drug in US markets. The USFDA noted in its report that the recall of affected lot is due to ‘blister package issues’. The lot was produced at Glenmark's Pithampur (Madhya Pradesh) based manufacturing facility. The USFDA stated that Glenmark initiated the Class II nationwide (US) recall on June 29 this year.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
